<DOC>
	<DOCNO>NCT01027260</DOCNO>
	<brief_summary>Patients suffer Irritable Bowel Syndrome predominant constipation provide study medication . The study medication evaluate efficacy relieving symptom</brief_summary>
	<brief_title>Study Evaluate Role Itopride HCI Patients With Irritable Bowel Syndrome With Predominant Constipation</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>1 . Male female patient fulfil Rome III criterion IBSC 2 . Signed informed consent screen visit 1 . Patients significant diarrhea least 25 % time past 3 month 2 . Patients alarm symptom sign 3 . Chronic diarrhea 4 . History gastrointestinal haemorrhage , mechanical obstruction perforation 5 . Patient clinically relevant ECG abnormality ( prolonged QT interval ) 6 . Active psychiatric disorder would interfere study objective 7 . Health condition ( e.g . age related impairment cognitive function ) would interfere study objective might impair compliance patient 8 . Severe hepatic , renal , cardiac , metabolic , haematological malignant disease ( include prolactin dependent tumour ) clinically relevant deviation laboratory value ( AST/ALT great twice upper limit normal , serum creatinine * 2 mg/dl [ 177 Âµmol/l ] accord medical judgement investigator 9 . Patient hypokalemia ( serum potassium &lt; 3.5 mmol/l ) . 10 . History known hypersensitivity ingredient investigational drug 11 . Pregnancy lactation 12 . Women childbearing potential apply medically accept method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>